Compare iShares MSCI South Africa ETF (EZA) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Natera Inc. Common Stock — how do they compare? iShares MSCI South Africa ETF trades at $63.18 (market cap $465.74M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 122.5× iShares MSCI South Africa ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 73 Days and Natera Inc. Common Stock for 0 Days on average.
| EZA | NTRA | |
|---|---|---|
Market Cap | $465.74M | $57.03B |
Volume | 245,187 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $425.64 |
52-Week Low | $60.43 | $179.42 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $64.32, up 0.86% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF, which tracks South African equities, faces headwinds from global reflation and higher capital costs impacting its financial and commodity-heavy holdings. Recent news highlighted a brief move above the 50-day average, but macro concerns dominate the narrative.
The outlook remains cautious due to exposure to volatile sectors like gold and banking amid rising rates. Investment opportunity hinges on South Africa's economic stability, but risks include commodity price pressures and unfavorable yield dynamics. Investor sentiment is neutral to bearish, with technicals suggesting near-term resistance at $64.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
